Immunochina obtained approval of clinical trial for IM19 CAR-T cells treatment for refractory or relapse non-Hodgkin’s lymphoma 04-152020

Learn More

Immunochina and Peking University Cancer Hospital participated in the ESMO 2019 annual meeting and showcased the latest progress in CAR-T research 10-022019

Learn More

Immunochina won the "2019 China Top 50 Healthcare Innovation Enterprises" 09-262019

Learn More

Immunochina was named as the star list-2019 China's top 50 biomedical companies with the most innovative power 08-122019

Learn More

Immunochina and Sijiqing County Exchange Forum 08-092019

Learn More